Many Clinically Stable CIDP Patients Can Safely Stop IVIG Maintenance Treatment
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.
Addition of Eltrombopag Improves Efficacy of Standard Therapy for Aplastic Anemia
Eltrombopay found to improve therapy for aplastic anemia.
Experimental Vaccine Developed to Prevent Rheumatoid Arthritis
Researchers at the University of Toledo have developed an experimental vaccine to prevent rheumatoid arthritis, one of the most common autoimmune disorders
COVID-19 Infection Alters Pregnant Mothers’ and Their Newborns’ Immunity
Investigators found COVID-19 infection altered the mothers’ immunity at delivery, and gestational COVID-19 exposure alters the immunity of newborns.
IG Treatment May Reduce Acute Exacerbations of COPD
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Study Shows COVID-19 Infection Correlates with Autoimmune Markers
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition from Clinic- to Home-Based IVIG/SCIG Is Successful to Decrease Exposure to COVID-19
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
Researchers Theorize Long COVID May Be an Autoimmune Disease
The National Institutes of Health is conducting a $470 million study to determine why COVID-19 symptoms persist for so long among many patients.
IVIG Plus Glucocorticoids Effective for Treating COVID-19 Pediatric Syndrome
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Kedrion to Market RYPLAZIM to Treat Rare Disease
Kedrion Biopharma is now marketing and distributing RYPLAZIM (plasminogen human-tvmh) in the United States to treat C-PLGD.